TFF Pharmaceuticals to Participate at The JMP Securities Life Sciences Conference
June 09, 2022 08:00 ET
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, June 09, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals to Participate at the Jefferies Healthcare Conference
June 01, 2022 08:00 ET
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, June 01, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals to Participate at the H.C. Wainwright Global Investment Conference
May 20, 2022 09:32 ET
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, May 20, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
May 11, 2022 16:01 ET
|
TFF Pharmaceuticals, Inc.
Announced Collaboration with Catalent to Further Expand Thin Film Freezing Applications with a Focus on Biologic Drug Development Announced Second CRADA Agreement with USAMRIID and Geneva Foundation...
TFF Pharmaceuticals Announces Multiple Presentations Highlighting Broad Applicability of its Thin Film Freezing Technology at Respiratory Drug Delivery Meeting (RDD)
May 02, 2022 08:00 ET
|
TFF Pharmaceuticals, Inc.
Thin Film Freezing Technology Co-Inventor Dr. Robert O. Williams III to Deliver Platform Presentation of Data on Stabilizing and Delivering Antivirals, Antibodies and Vaccines using Thin Film Freezing...
TFF Pharmaceuticals to Hold First Quarter 2022 Financial and Business Results Conference Call on May 11, 2022
April 29, 2022 07:30 ET
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, April 29, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Announces Safety and Pharmacokinetic Data from Phase 1 Study of Niclosamide Inhalation Powder
April 19, 2022 08:00 ET
|
TFF Pharmaceuticals, Inc.
Niclosamide Inhalation Powder Well Tolerated with No Serious Adverse Events Across All Subject Cohorts Current Data Suggests Niclosamide Inhalation Powder is a Promising Antiviral Treatment to Combat...
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
March 24, 2022 16:26 ET
|
TFF Pharmaceuticals, Inc.
Pipeline Advancement Continues with Ongoing Phase 2 Studies for Voriconazole and Tacrolimus Programs Partnership Activity Surrounding Thin Film Freezing Continues to Expand Reflecting the...
TFF Pharmaceuticals Enters into CRADA with the U.S. Army and The Geneva Foundation to Develop Dry Powder Needle-free Medical Countermeasures
March 17, 2022 08:00 ET
|
TFF Pharmaceuticals, Inc.
AUSTIN, Texas, March 17, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals to Participate at the 34th Annual Roth Conference
March 11, 2022 07:05 ET
|
TFF Pharmaceuticals, Inc.
AUSTIN, Texas, March 11, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...